Compare Stocks Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities. Stocks to Compare Sections All Sections Selected Performance Chart Price & Volume MarketRank Analyst Ratings Sales & Book Value Profitability & Earnings Dividends Debt Ownership Miscellaneous Headlines About Compare NASDAQ:BDSX NASDAQ:BNR NASDAQ:DCGO NASDAQ:LFMD On This Page Performance ChartPrice & VolumeMarketRank™Analyst RatingsSales & Book ValueProfitability & EarningsDividendsDebtOwnershipMiscellaneousHeadlinesAbout Comparison Ideas Stock Ideas Comparative Price Performance Over Time1 day7 days30 days90 days365 daysCompare Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeBDSXBiodesix$14.93$14.09$5.00▼$20.21$150.93M0.4374,905 shs30,179 shsBNRBurning Rock Biotech$14.51$17.74$2.80▼$41.72$152.62M1.4918,703 shs24,860 shsDCGODocGo$0.63$0.62$0.49▼$1.78$62.26M1.02549,539 shs337,353 shsLFMDLifeMD$4.19$4.15$2.56▼$15.84$202.64M2.031.01 million shs722,163 shs The Best Nuclear Energy Stocks to BuyNuclear energy is entering a new growth cycle as rising power demand, expanding data centers, and renewed policy support bring the sector back into focus. After strong gains in recent years, the most impactful phase of nuclear investment may still be ahead. This report highlights seven nuclear energy stocks positioned across the value chain—combining near-term revenue with long-term upside as next-generation technologies scale. Click the link below to unlock the full list.Get This Free ReportCompare Price PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceBDSXBiodesix0.00%+5.36%+40.32%+16.91%+117.89%BNRBurning Rock Biotech0.00%-14.85%-29.87%-49.62%+342.38%DCGODocGo0.00%+10.40%-12.19%-14.92%-52.95%LFMDLifeMD0.00%-3.23%-9.70%+58.71%-63.66%Compare Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeBDSXBiodesix$14.93$14.09$5.00▼$20.21$150.93M0.4374,905 shs30,179 shsBNRBurning Rock Biotech$14.51$17.74$2.80▼$41.72$152.62M1.4918,703 shs24,860 shsDCGODocGo$0.63$0.62$0.49▼$1.78$62.26M1.02549,539 shs337,353 shsLFMDLifeMD$4.19$4.15$2.56▼$15.84$202.64M2.031.01 million shs722,163 shs The Best Nuclear Energy Stocks to BuyNuclear energy is entering a new growth cycle as rising power demand, expanding data centers, and renewed policy support bring the sector back into focus. After strong gains in recent years, the most impactful phase of nuclear investment may still be ahead. This report highlights seven nuclear energy stocks positioned across the value chain—combining near-term revenue with long-term upside as next-generation technologies scale. Click the link below to unlock the full list.Get This Free ReportCompare Price PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceBDSXBiodesix0.00%+5.36%+40.32%+16.91%+117.89%BNRBurning Rock Biotech0.00%-14.85%-29.87%-49.62%+342.38%DCGODocGo0.00%+10.40%-12.19%-14.92%-52.95%LFMDLifeMD0.00%-3.23%-9.70%+58.71%-63.66%Compare Analyst ForecastsCompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current PriceBDSXBiodesix 2.33Hold$22.0047.35% UpsideBNRBurning Rock Biotech 1.00SellN/AN/ADCGODocGo 2.33Hold$2.38276.69% UpsideLFMDLifeMD 2.67Moderate Buy$9.14118.21% UpsideCurrent Analyst Ratings BreakdownLatest DCGO, LFMD, BNR, and BDSX Analyst RatingsDateCompanyBrokerageActionRatingPrice TargetDetails5/18/2026BDSXBiodesix Weiss RatingsSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingDowngradeSell (D-) ➝ Sell (E+)5/11/2026DCGODocGo Cantor FitzgeraldSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingOverweight5/7/2026LFMDLifeMD Weiss RatingsSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingUpgradeSell (E+) ➝ Sell (D)5/5/2026BDSXBiodesix Canaccord Genuity GroupSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingBoost Price TargetBuy$20.00 ➝ $22.005/4/2026BDSXBiodesix Weiss RatingsSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingSell (D-)5/4/2026LFMDLifeMD BTIG ResearchSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingBuy$10.004/20/2026BNRBurning Rock Biotech Weiss RatingsSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingSell (D-)3/27/2026LFMDLifeMD Weiss RatingsSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingSell (E+)3/25/2026DCGODocGo Canaccord Genuity GroupSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingLower Price TargetHold$1.50 ➝ $1.003/17/2026DCGODocGo Stifel NicolausSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingLower Price TargetBuy$4.00 ➝ $2.503/17/2026DCGODocGo Cantor FitzgeraldSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingOverweight$3.00(Data available from 5/25/2023 forward. View 10+ years of historical ratings with our analyst ratings screener.)Compare Sales & Book ValueCompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/BookBDSXBiodesix$88.50M1.71N/AN/A$0.90 per share16.59BNRBurning Rock Biotech$77.16M1.98N/AN/A$7.28 per share1.99DCGODocGo$322.20M0.19$0.06 per share11.39$1.13 per share0.56LFMDLifeMD$194.05M1.04N/AN/A$0.31 per share13.52Compare Profitability & EarningsCompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings DateBDSXBiodesix-$35.26M-$4.06N/AN/AN/A-33.26%-2,101.40%-35.65%8/6/2026 (Estimated)BNRBurning Rock Biotech-$7.92M-$0.79N/AN/AN/A-10.27%-9.98%-6.69%6/2/2026 (Estimated)DCGODocGo-$182.40M-$1.91N/A12.61N/A-62.23%-44.09%-29.14%8/6/2026 (Estimated)LFMDLifeMD$14.35M$0.0583.8211.32N/A2.37%-150.88%-22.59%8/5/2026 (Estimated)Latest DCGO, LFMD, BNR, and BDSX EarningsDateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails6/2/2026Q1 2026BNRBurning Rock Biotech-$2.2884N/AN/AN/A$19.21 millionN/A5/11/2026Q1 2026DCGODocGo-$0.02-$0.12-$0.10-$0.15$72.48 million$75.55 million5/6/2026Q1 2026LFMDLifeMD-$0.14-$0.20-$0.06-$0.20$48.84 million$50.16 million5/4/2026Q1 2026BDSXBiodesix-$1.1298-$0.81+$0.3198-$0.81$23.12 million$25.56 million3/13/2026Q4 2025BNRBurning Rock BiotechN/A-$0.21N/A-$0.21N/A$18.05 million3/9/2026Q4 2025LFMDLifeMD-$0.01-$0.04-$0.03$0.41$48.57 million$46.87 million2/26/2026Q4 2025BDSXBiodesix-$1.05-$0.49+$0.56-$0.49$26.25 million$28.76 millionCompare DividendsCompanyAnnual PayoutDividend Yield5-Year Annualized Dividend GrowthPayout RatioYears of Consecutive GrowthBDSXBiodesixN/AN/AN/AN/AN/ABNRBurning Rock BiotechN/AN/AN/AN/AN/ADCGODocGoN/AN/AN/AN/AN/ALFMDLifeMDN/AN/AN/AN/AN/ACompare DebtCompanyDebt-to-Equity RatioCurrent RatioQuick RatioBDSXBiodesix5.092.822.82BNRBurning Rock BiotechN/A2.992.79DCGODocGoN/A1.791.79LFMDLifeMDN/A1.040.98Compare OwnershipInstitutional OwnershipCompanyInstitutional OwnershipBDSXBiodesix20.96%BNRBurning Rock Biotech30.03%DCGODocGo56.44%LFMDLifeMD35.52%Insider OwnershipCompanyInsider OwnershipBDSXBiodesix23.20%BNRBurning Rock Biotech30.30%DCGODocGo3.80%LFMDLifeMD18.40%Compare Miscellaneous StatsCompanyEmployeesShares OutstandingFree FloatOptionableBDSXBiodesix22010.11 million7.76 millionNo DataBNRBurning Rock Biotech1,39010.52 million7.33 millionNot OptionableDCGODocGo3,56898.75 million95.00 millionOptionableLFMDLifeMD23048.36 million39.46 millionOptionableDCGO, LFMD, BNR, and BDSX HeadlinesRecent News About These CompaniesLifeMD to Participate in Upcoming Investor ConferencesMay 15, 2026 | globenewswire.comLifeMD (NASDAQ:LFMD) Cut to Sell at Wall Street ZenMay 9, 2026 | marketbeat.comLifeMD, Inc. (LFMD) Q1 2026 Earnings Call TranscriptMay 6, 2026 | seekingalpha.comLifeMD Q1 Earnings Call HighlightsMay 6, 2026 | marketbeat.comLifeMD (NASDAQ:LFMD) Posts Quarterly Earnings Results, Misses Estimates By $0.06 EPSMay 6, 2026 | marketbeat.comLifeMD, Inc. (LFMD) Reports Q1 Loss, Tops Revenue EstimatesMay 6, 2026 | zacks.comLifeMD Reports First Quarter 2026 ResultsMay 6, 2026 | globenewswire.comLifeMD, Inc. (NASDAQ:LFMD) Receives Average Recommendation of "Moderate Buy" from AnalystsMay 6, 2026 | marketbeat.comLifeMD's (LFMD) Buy Rating Reiterated at BTIG ResearchMay 4, 2026 | marketbeat.comLifeMD (LFMD) Projected to Post Quarterly Earnings on TuesdayApril 28, 2026 | marketbeat.comLifeMD to Report First Quarter 2026 Financial Results on May 6April 27, 2026 | globenewswire.comLifeMD (LFMD) Soars 23.7%: Is Further Upside Left in the Stock?April 21, 2026 | zacks.comLifeMD Shares Rise After Offering Lilly's GLP-1 Obesity PillApril 20, 2026 | marketwatch.comLifeMD® Now Offering Eli Lilly and Company's Foundayo™ (orforglipron), a New GLP-1 Pill for Weight ManagementApril 10, 2026 | globenewswire.comNovo to sell Wegovy subscriptions on Hims, LifeMD, and othersApril 1, 2026 | seekingalpha.comLifeMD Offers Novo Nordisk's Industry-First Wegovy® Telehealth Subscription ProgramMarch 31, 2026 | globenewswire.comLifeMD Declares Quarterly Dividend on Series A Cumulative Perpetual Preferred StockMarch 24, 2026 | globenewswire.comLifeMD Taps Kavthekar as CFOMarch 16, 2026 | marketwatch.comLifeMD Appoints Veteran Healthcare Finance Executive as Chief Financial Officer and Expands Leadership TeamMarch 16, 2026 | globenewswire.comLifeMD: Wegovy Pill, Net Cash, And Low Multiple Sets Up Longs For Possible AlphaMarch 11, 2026 | seekingalpha.comLifeMD, Inc. (LFMD) Q4 2025 Earnings Call TranscriptMarch 9, 2026 | seekingalpha.comNew MarketBeat Followers Over TimeMedia Sentiment Over TimeDCGO, LFMD, BNR, and BDSX Company DescriptionsBiodesix NASDAQ:BDSX$14.93 0.00 (0.00%) Closing price 05/22/2026 04:00 PM EasternExtended Trading$15.50 +0.57 (+3.78%) As of 05/22/2026 06:15 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more.Biodesix, Inc. operates as a data-driven diagnostic solutions company in the United States. The company offers blood-based lung tests, including Nodify XL2 and Nodify CDT tests, together marketed as part of Nodify Lung Nodule Risk Assessment testing strategy, to assess the risk of lung cancer and help in identifying the appropriate treatment pathway and help physicians in reclassifying risk of malignancy in patients with suspicious lung nodules. It also provides GeneStrat ddPCR and NGS, and VeriStrat tests, which are used in the diagnosis of lung cancer to measure the presence of mutations in the tumor and the state of the patient's immune system to establish the patient's prognosis and help guide treatment decisions. In addition, the company, through its partnership with Bio-Rad Laboratories, Inc., provides Bio-Rad SARS-CoV-2 ddPCR, a COVID-19 Test under Biodesix WorkSafe testing program; and Platelia SARS-CoV-2 Total Ab test, an antibody test for detecting a B-cell immune response to SARS-CoV-2 that indicate recent or prior infection. Further, it offers diagnostic and clinical research, as well as clinical trial testing services to biopharmaceutical companies; and discovers, develops, and commercializes companion diagnostics. The company was formerly known as Elston Technologies, Inc. and as changed to Biodesix, Inc. in 2006. Biodesix, Inc. was incorporated in 2005 and is headquartered in Louisville, Colorado.Burning Rock Biotech NASDAQ:BNR$14.51 0.00 (0.00%) Closing price 05/22/2026 04:00 PM EasternExtended Trading$15.25 +0.74 (+5.10%) As of 05/22/2026 06:29 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more.Burning Rock Biotech Limited primarily develops and commercializes cancer therapy selection tests in the People's Republic of China. It operates in three segments: Central Laboratory Business, In-Hospital Business, and Pharma Research and Development Services. The company primarily offers next-generation sequencing-based tissue and liquid biopsy cancer therapy selection and prognosis prediction tests for various range of cancer types, including lung cancer, gastrointestinal cancer, prostate cancer, breast cancer, lymphomas, thyroid cancer, colorectal cancer, ovarian cancer, pancreatic cancer, and bladder cancer using tissue and liquid biopsy samples. Its principal products include OncoCompass IO, a corresponding test for liquid biopsy samples; OncoScreen IO, a pan-cancer test for tissue samples; and OncoCompass Target, a ctDNA liquid biopsy-based test for NSCLC. In addition, the company provides ColonCore for assessing microsatellite loci related to MSI status and detecting mutations in genes associated with gastrointestinal cancers; and brPROPHET, a pre-operative ctDNA detection and post-operative MRD calling for relapsed patients. Further, it has development and commercialization agreement with Myriad Genetics, Inc. to in-license Myriad myChoice tumor testing in China; licensing agreement with Oncocyte Corporation to in-license DetermaRx, a risk stratification test for early stage lung cancer patients in China; and collaborations on clinical trials and research studies with AstraZeneca, Bayer, Johnson & Johnson, CStone, BeiGene, Abbisko Therapeutics, and IMPACT Therapeutics and Merck KGaA. Additionally, the company offers OncoMaster, an automatic NGS data analysis and report interpretation machine for in-hospital model. Burning Rock Biotech Limited was incorporated in 2014 and is headquartered in Guangzhou, China.DocGo NASDAQ:DCGO$0.63 0.00 (0.00%) Closing price 05/22/2026 04:00 PM EasternExtended Trading$0.64 +0.01 (+1.03%) As of 05/22/2026 07:50 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more.DocGo Inc. provides mobile health and medical transportation services for various health care providers in the United States and the United Kingdom. The company's transportation services include emergency response services; and non-emergency transport services comprise ambulance and wheelchair transportation services. It also offers mobile health services through its platform that are performed at home, offices, and other locations; event services, which include on-site healthcare support at sporting events and concerts; and total care management solutions comprising healthcare services and ancillary services, such as shelter. DocGo Inc. was founded in 2015 and is headquartered in New York, New York.LifeMD NASDAQ:LFMD$4.19 0.00 (0.00%) Closing price 05/22/2026 04:00 PM EasternExtended Trading$4.20 +0.00 (+0.12%) As of 05/22/2026 07:05 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more.LifeMD, Inc. operates as a direct-to-patient telehealth company that connects consumers to healthcare professionals for medical care in the United States. The company offers telehealth platform comprising RexMD, a men's telehealth brand that provides access to virtual medical treatment for a variety of men's health needs from licensed physician; ShapiroMD that provides virtual medical treatment, prescription medications, patented doctor formulated OTC products, topical compounded medications, and medical devices treating male and female hair loss; NavaMD, a female-oriented tele-dermatology that offers virtual medical treatment from dermatologists and other providers; and prescription oral and compounded topical medications to treat aging and acne; and Cleared which provides personalized treatments for allergy, asthma and immunology, including in-home tests for both environmental and food allergies, prescriptions for allergies and asthma and immunotherapies for treating chronic allergies. It also provides LifeMD PC, a direct-to-consumer virtual primary care which includes 24/7 access to a provider for their primary care, urgent care, and chronic care needs; and offers virtual consultations and treatment, prescription medications, diagnostics and imaging, wellness coaching, and more. In addition, the company offers PDFSimpli, an online software as a service platform that allows users to create, edit, convert, sign, and share PDF documents; ResumeBuild which provides digital resume and cover letter services; SignSimpli, a digital signature platform; and LegalSimpli, a provider of legal forms for consumers and small businesses. It sells its products directly to consumers and through e-commerce platforms, as well as through third party partner channels. The company was formerly known as Conversion Labs, Inc. and changed its name to LifeMD, Inc. in February 2021. LifeMD, Inc. was incorporated in 1994 and is headquartered in New York, New York. More Stock Comparisions from MarketBeat Stock Comparison Ideas (A-K)5GAgricultureAirlineAmerica FirstApparelArtificial IntelligenceAutomotiveBankBiotechBitcoinBlockchainBlue ChipCanadianCannabisCasinoChatGPTChineseCloud StorageCryptocurrencyCybersecurityDefenseDividendDow 30DroneEcommerceElectric VehiclesEnergyEntertainmenteSportsEV ChargingFertilizerFlying CarGoldGroceryGrowthHealthcareHigh DividendHotelStock Comparison Ideas (L-Z)Large CapLeisureLithiumMade In AmericaMagnificent SevenMega CapMemeMetaverseMid CapMiningMusic IndustryNanotechnologyNFTNuclear EnergyOilPharmaceuticalQuantum ComputingRenewable EnergyRestaurantRetailSemiconductorSilverSocial MediaSolarSpaceTechnologyTelecomToyUraniumUtilityVideo GameVirtual RealityWallStreetBets More Stock Ideas from MarketBeat Stock Lists 5G Stocks Biotech Stocks Blue Chip Stocks DOW 30 Stocks FAANG Stocks Gold Stocks Large Cap Stocks Lumber Stocks Marijuana Stocks Micro Cap Stocks Oil Stocks REITs Small Cap Stocks SPACs Travel Stocks Trillion Dollar Stocks Water Stocks Warren Buffett Stocks Low Priced Stocks Penny Stock List Popular Penny Stocks Top Stocks Today Stocks on Sale Stocks Under $0.05 Stocks Under $0.10 Stocks Under $0.25 Stocks Under $0.50 Stocks Under $1 Stocks Under $2 Stocks Under $3 Stocks Under $5 Stocks Under $10 Stocks Under $20 Stocks Under $30 Stocks Under $50 Stocks By Exchange NASDAQ Stocks NYSE Stocks NYSEAMERICAN Stocks NYSEARCA Stocks NYSEMKT Stocks OTCMKTS Stocks TSX Stocks TSXV Stocks LSE Stocks BATS Stocks Latest Stock Ideas MarketBeat Week in Review – 05/18 - 05/22 Ross Stores Earnings Beat Sends Stock To New Highs Was Decker’s Double Beat a Bullish Signal—Or Mere HOKA’s-Pocus? Workday Validates AI Flywheel: Stock Price Recovery Begins Apparel Earnings Winners and Losers: Ralph Lauren Takes Off SpaceX IPO: Opportunity? Or the Ultimate Hype Trade? The Careful Consumer: What Q1 Earnings Reveal—And Where Cracks May Appear Overextended, e.l.f. Beauty Is Primed to Rebound in Back Half Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In Email Me a Login Link or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
